153 results about "Transmissible disease" patented technology

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.

The invention constructs a universal visual virus molecularly imprinted sensor modified with an anti-protein coating, the sensor uses magnetic Fe3O4 as an imprinting carrier, HBV as a template and dopamine as a functional monomer for imprinting to obtain a molecularly imprinted polymer with a polydopamine coating (PDA), and before the template is removed, the molecular imprinting polymer with the polydopamine coating (PDA) is separated from the template, so that the molecular imprinting polymer with the polydopamine coating (PDA) is obtained. The surface of the PDA layer is covered with a slightly cross-linked PMEO2MA layer through a water precipitation polymerization method, and the polymer can effectively reduce non-specific protein adsorption; and finally, exposing an imprinting cavity of the PDA layer by eluting the template molecules. On the other hand, potassium permanganate (KMnO4) is used as a signal output molecule, and when no target object exists, the strong reducibility of PDA can enable KMnO4 entering the imprinting cavity to be subjected to a color fading reaction. Based on the principle, high-specificity colorimetric visual detection on the HBV is realized. The sensor can be combined with a smart phone through naked eyes to carry out visual semi-quantitative analysis and carry out quantitative detection through ultraviolet rays, and the universality of the sensor can be confirmed through a template replacement experiment. And meanwhile, the sensor shows an excellent cost advantage. The diagnosis which is high in sensitivity, low in cost and capable of achieving rapid visualization shows huge potential in practical application, and particularly has important application value in infectious disease screening and monitoring work in areas with limited resources.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present invention relates to a novel lipid compound for tissue-specific delivery, and a lipid nano-particle (LNP) composition comprising the same, the lipid nano-particle comprising a modified lipid compound as a component, according to the present invention, internal active substances are selectively delivered into cells of specific tissues such as lymph nodes, spleen, retina, cancer, brain, liver and the like in vivo, thereby preventing side effects and safely exhibiting a desired level of effect. The tissue-specific non-viral LNP delivery vectors can be effectively used for prevention of infectious diseases and treatment of rare and refractory (hereditary) diseases (diseases which are effectively and selectively delivered to in-vivo targeted sites, such as macular degeneration, diabetic retinal degeneration, hereditary retinal degeneration, cancer, cerebral diseases, liver diseases and the like).

The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.

The invention provides a method and a kit for quantitative detection of recombinant redistribution of a Databa virus based on a multiple digital PCR (Polymerase Chain Reaction) technology, and belongs to the field of infectious disease monitoring. The method comprises the following steps: providing a to-be-detected sample containing segmented viruses and viral nucleic acid; detecting nucleic acid by using a plurality of multiple digital PCR reaction systems containing specific primer pairs and fluorescence labeled probes; amplifying according to a fluorescence coding rule, collecting and analyzing multi-channel fluorescence signals, and calculating the absolute copy number of each genotype; and based on copy number analysis genotype intra-fragment distribution proportion and inter-fragment combination mode, evaluating characteristics and frequency of virus recombination reconfiguration events. According to the detection method and the kit provided by the invention, accurate quantification of all main genotypes of the Databa virus can be realized.

The present invention is a two-state feedback controller that takes into account the influence of spatio-temporal diffusion and individual contact heterogeneity. The controller design method includes: Step 1: Establish an SIR epidemic model; Step 2: Apply a two-state feedback controller to the SIR epidemic model; Step 3: Linearize the SIR epidemic model under the action of the two-state feedback controller at the equilibrium point to obtain the characteristic equation of the linearized controlled SIR epidemic model; Step 4: Select the time delay as the bifurcation parameter, and through stability analysis and bifurcation analysis of the characteristic equation of the linearized controlled SIR epidemic model, select appropriate state feedback parameters to make the model locally asymptotically stable near the equilibrium point. The two-state feedback controller of the present invention can perform feedback regulation control according to the state variables of susceptible individuals and infected individuals at the same time, and does not affect the characteristics of the original system, so as to efficiently and safely regulate the virus transmission process.

The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and / or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and / or treating cancer or infectious disease.

A combined Chinese yam tuber growth groove arranged in a trench belongs to agricultural planting appliances, the Chinese yam tuber growth groove comprises a combination part, a space part and a base, the combination part is used for overlapping an upper Chinese yam tuber growth groove and a lower Chinese yam tuber growth groove, and the Chinese yam tuber growth grooves are combined to form a Chinese yam tuber growth space. According to the Chinese yam tuber growing device, Chinese yam tubers are separated from soil, occurrence of soil infectious diseases is avoided, growth resistance of the Chinese yam tubers is reduced, and the Chinese yam tuber growing device has the advantages that the Chinese yam tuber growing device is simple in structure, convenient to use and high in yield, and the yield of the Chinese yam tubers is increased. Chinese yam tubers grow in the shallow soil layer, the planting density is increased, the tower furrow phenomenon is avoided, the yield and quality of Chinese yams are improved, the plot planting limitation is overcome, the planting range is expanded, mechanical planting is achieved, and the income of farmers is increased.

The present disclosure relates to compositions comprising lipid nanoparticles (LNPs) configured for targeting dendritic cells. In particular, the present disclosure provides LNPs comprising a serine-based helper-lipid, a PEG lipid, an ionizable lipid, a cholesterol component, and one or more nucleic acids. The present disclosure provides use of the LNPs for the delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in various therapeutics, such as for the treatment of cancer or autoimmune diseases or prevention of infectious diseases. Finally, methods are provided for preparing such LNPs.

Provided is a dendritic cell activator that contains, as an active ingredient, a component derived from a natural product which has been eaten for many years and the safety of which has been empirically confirmed, and that is used for inducing or promoting an acquired immune response effective against cancer or infectious disease. Specifically provided are: a dendritic cell activator containing, as an active ingredient, 5-(3,5-dihydroxyphenyl)-y-valerolactone represented by formula (I); and a medicine, a supplement, and a food or beverage each containing the compound represented by formula (I) as an active ingredient. [The configuration of the wavy line may be either R-form or S-form.]

Disclosed are substituted indole compounds and compositions. The substituted indole compounds and compositions can be used for treating or preventing acute renal failure in a subject. The compounds and compositions can also be used for treating an infectious disease or cancer.

Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and / or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen.

The present invention provides an mRNA element, a system, and a use. A UPA-containing uncapped linear mRNA of the present invention can be efficiently and stably expressed without adding a 5' cap or adding a nucleic acid modification in an in vitro transcription synthesis process, and can be used as an infectious disease vaccine or tumor vaccine expression system.

The application of unilateral or bilateral permanent prostheses to the labium majus in the external genitalia of women for reconstructive and aesthetic purposes may make it appear fuller. The labium majus may lose its fullness and symmetry due to menopause, rapid weight gain and loss, traumas, cancers, and infectious diseases. Aesthetic interventions (e.g., hyaluronic acid filler injection and fat grafting) aiming to provide the labium majus with fullness have become very popular in recent years. The hyaluronic acid filler is used for reconstructive purposes to achieve fullness in labium majus. However, the maximum amount that can be injected is 3 mL, which is often insufficient for the desired outcome and its effect lasts for a maximum of 1 year. Autologous fat grafting is administered by taking 18–120 mL of fat from patients themselves; however, its effect usually lasts 1 to 4 years. The application of a prosthesis will provide labium majus with fullness and this effect will be long-lasting. The outer edge of the prosthesis is convex and the inner edge is concave. In male genitalia, prostheses have been used since 1950 to provide the testicles with fullness. Scientific studies have shown that these prostheses positively affect self-confidence and body perception indices in men.

Disclosed are an artificial lymph node (aLN) comprising an extracellular matrix (ECM) hydrogel conjugated with an antigen presenting complex (Signal 1), a co-stimulatory ligand (Signal 2), and T cell-stimulating cytokine (Signal 3) and methods of their use for stimulating one or more T cells and treating a disease, disorder, or condition selected from a cancer, an infectious disease, and an autoimmune disease.

The invention provides a targeted mRNA delivery system of muscle tissues and / or muscle cells based on aptamer functionalized LNP (Apt-LNP), the delivery system can significantly improve mRNA transfection of the muscle tissues, and meanwhile, mRNA expression in main organs such as liver and spleen is greatly reduced. The expression intensity of muscle tissue in-situ mRNA is improved through modification of the aptamer, meanwhile, mRNA expression in main organs such as the liver and the spleen is greatly reduced, and side effects caused by off-target of mRNA infectious disease vaccines are expected to be avoided. The method is expected to be applied to the field of infectious disease mRNA vaccines The invention also provides a targeting mRNA delivery system of lymph node tissues and / or immune cells based on the aptamer functionalized LNP (Apt-LNP). Compared with an existing lymph node targeting system, the Apt-LNP modified by the aptamer not only can realize lymph node mRNA targeting, but also can further target immune cells, and is expected to be applied to the field of tumor mRNA vaccines to enhance the curative effect of tumor vaccines.

An immunotherapeutic mRNA vaccine comprises a first translation unit comprising a secretable first fusion protein comprising a co-stimulatory molecule fused to a first TAA, adapted to generate a first TAA specific adaptive immune response by way of a first immunostimulatory pathway. The immunotherapeutic mRNA vaccine also comprises a second translation unit comprising a non-secretable second fusion protein comprising an identical co-stimulatory molecule fused to a second TAA identical to the first TAA, adapted to generate a second TAA specific adaptive immune response by way of a second immunostimulatory pathway, whereby the at least two immune response interact at one or more locations downstream to amplify the first TAA specific adaptive immune response.

The application relates to the diagnosis and treatment of diseases, including cancer, chronic infectious diseases, autoimmune diseases, inflammatory disorders, as well as the prevention of transplant rejection. The invention provides, and involves the use of, antibody molecules that bind CD28 in a non super-agonistic manner and which also bind to CTLA-4. The antibody molecules may form part of a bispecific molecule which binds e.g. a tumor associated antigen or a further T cell antigen, such as CD3.

The disclosure describes poly(β-thioester) polymers and polymeric nanoparticles, pharmaceutical compositions comprising these materials, their use in the treatment of cancer and infectious disease, and machine learning methods for identifying and selecting them.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present invention is related to human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles and their use in medicine, particularly for the prevention and / or treatment of inflammatory driven diseases, neurodegenerative diseases, immune / autoimmune diseases, cardiovascular diseases, dermatologic diseases, orthopedic diseases, tissue regenerative medicine, oncologic diseases, infectious diseases, transplant rejections, stroke, ischemia or Graft-versus-Host Disease. The present invention is further related to a method of manufacture of a pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation comprising the step of adding human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles to the pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation.

The present disclosure relates to methods, compositions, and kits for enriching and purifying at least one target analyte from a clinical biological sample. In some embodiments, the methods involve one or more aqueous two-phase system (ATPS) compositions and at least one solid phase medium. Some embodiments provide kits including one or more ATPS compositions, a binding buffer, and a solid phase medium. Other embodiments provide methods for treating cancer or an infectious disease in a patient in need thereof.

Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and / or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen.

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

Degradable polymers were synthesized that self-assemble with nucleic acids, proteins, hydrophobic drugs, and other small molecules to form particles that are effective for delivery into a cell, tissue and / or organism either in vitro or in vivo. The presently disclosed polymers demonstrate differential cell-type specificity, an ability to promote endosomal escape to protect the cargos from degradation and enhance delivery to the cytoplasm, and / or bioreducibility, which enables triggered intracellular drug release to be tuned to promote optimal delivery to the target cell type. The presently disclosed materials may be used to treat a wide variety of conditions or diseases, such as cancer, cardiovascular diseases, infectious diseases, and ophthalmic diseases.

The present disclosure provides improved compositions for adoptive T cell therapy for treating, preventing, or ameliorating at least one symptom of cancer, infectious diseases, autoimmune diseases, inflammatory diseases, and immunodeficiency, or conditions associated therewith.

The present invention provides antibodies or antigen-binding fragments thereof that specifically bind to human PD-L2, as well as novel complementarity determining regions CDR1, CDR2 and CDR3 for each heavy chain and light chain of the antibodies. The antibodies or antigen-binding fragments have uses in enhancing T cell function, as well as treating cancer and acute or chronic infectious diseases.